Hallucinations? Delusions? Paranoia? Anxiety?
If you or someone you love is experiencing any of the above symptoms and is diagnosed with a neurodegenerative disease, it may be disease related behavioral symptoms.
While there is currently no treatment that does not worse the progression of the disease, Acadia Pharmaceuticals and Insight Clinical Trials may be able to help. Currently, we are seeking volunteers for a research study to examine if Pimavanserin is an effective treatment for behavioral symptoms related to neurodegenerative diseases.
"Psychosis has been recognized as a common feature in
neurodegenerative disease for many years. Halluncinations, delusions, and other psychotic phenomena occur in a wide range of degenerative disorders"
- University of Pennsylvania School of Medicine
Who Is Eligible?
Participants must be at least 60 years old
Require assistance with daily living
Diagnosed with: mild cognitive impairment, Parkinson's, Lewy body dementia, Alzheimer's disease, vascular dementia or another neurodegenerative disease
Has a designated, reliable study partner/caregiver
How Does It Work?
Eligible patients will be randomly assigned to receive either the investigational drug or placebo. There is a 50% chance of receiving either. Patients, study doctors, and study staff will not know the study drug assignments. This study consists of eight visits over approximately 16 weeks. During each visit, study staff will conduct various tests and assessments to evaluate the patient's health and progress.
Risks and Benefits
As with any research study, there are both risks and benefits. Benefits include additional care and monitoring as well as compensation for your time and participation in the study. It is possible that patients may experience one or more side effects. The most common are confusion, nausea, constipation and edema. A less common but serious side effect is abnormal heart rhythm.
Pimavanserin (NUPLAZID) is an atypical antipsychotic medication that is U.S. FDA approved for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. The data from previous studies of Pimavanserin support the investigation of Pimavanserin as a treatment for dementia-related psychosis, agitaition and aggression in other neurodegenerative diseases.
To see if you may pre-qualify for the study, call Insight Clinical Trials at (216) 526-1843 or fill out this form.